Navigation Links
Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
Date:11/10/2008

ed on the localized and sustained cardiac production of insulin-like growth factor-1 (IGF-1) following a one-time intracoronary administration in an acute care setting immediately after percutaneous coronary intervention in heart attack patients. Data from the pre-clinical study is expected to be announced in early 2009 and is designed to support the clinical potential of Corgentin. The long-term safety and efficacy of IGF-1 protein-based drugs that have already been approved by the FDA for the treatment of short stature children, are based on daily treatments for periods of a year or more. This data provides significant insights into the potential safety relating to a one-time DNA-based IGF-1 Corgentin treatment.

Commentary

"The recent FDA 510(k) clearance for our RapidBlue System, which we believe is the most powerful and easiest to use endovascular-based system in the world, represented a key milestone in completing Cardium's turnaround and strategic reposition of the Company's InnerCool investment," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium. "We are continuing to develop a portfolio of uniquely positioned medical device products based on our platform technology and expertise in the growing field of temperature modulation therapy. These new product opportunities, like our new UroCool Targeted Tissue Cooling System, are being developed for specific and defined vertical markets transactioned through strategic alignments, financings and other structured deals in keeping with our ongoing strategy to monetize InnerCool."

Reinhard added, "During this difficult economic period, we believe we have established a balanced plan to move our businesses forward, with a principal focus on completion of near-term milestones including the MATRIX clinical study for Tissue Repair's Excellarate candidate for non-healing diabetic wounds, and advancement of InnerCool's portfolio of therapeutic hypothermia products, each of whi
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
2. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
3. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
4. Cardium Announces Follow-On Direct Investment by Institutional Investor
5. Cardium Selected for Inclusion in Russell Microcap Index
6. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
7. Cardium Launches New AWARE Clinical Study Website
8. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Cardium Reports on First Quarter 2008 Highlights and Financial Results
11. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 Today, Nerium ... announced the winners of its “Reflect Your Youth” contest, ... not only seen a difference in their skin since ... a new outlook on life as a result of ... originated as an effort by Nerium International to inspire ...
(Date:10/25/2014)... and NEW YORK , Oct. ... ACCPD), formerly Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical ... it has implemented a 1-for-50 reverse split of ... trading on Friday, October 24, 2014. PlasmaTech,s common ... new CUSIP number 72754H109 and temporary ticker symbol ...
(Date:10/22/2014)... -- New test innovations will be the source of ... industry, especially as companies struggle with reimbursement challenges, according ... 25 testing innovations in important disease areas in academic ... details the new approaches its biennial survey of the ... Diagnostic Tests , 9th Edition . ...
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open ... the pain management and clinical markets. The software increases ... by allowing users to highlight and review results that ... allows analysts to filter results by group or based ... eliminating the need to sift through analytes of no ...
Breaking Biology Technology:Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2
... 9 A homegrown New Jersey company is,earning ... of pharmaceuticals everywhere. Secure Symbology, (http://www.securesymbology.com ), a ... an,Honored Finalist as Emerging Business of the Year ... its vision to wipe out counterfeit drugs,worldwide. ...
... Extension Provides Members of University HealthSystem Consortium With Broad ... ... 9 Baxter International,Inc. (NYSE: BAX ) announced today ... signed a new two-year,contract extension on behalf of UHC valued ...
... Cell Therapeutics, Inc. (CTI),(Nasdaq: CTIC ; MTAX) management will present at ... pm at,the Palace Hotel in San Francisco. The conference will also ... webcast can be accessed at, http://www.cticseattle.com . ... BIO CEO & Investor Conference ...
Cached Biology Technology:Secure Symbology: Making New Jersey Proud While Saving Lives 2Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products 2Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products 3
(Date:10/17/2014)... have shown for the first time how bacteria can ... giving them the opportunity to get tremendous insights into ... study also discovered the bacterial growth in chronic lung ... slowed down by the immune cells. The researchers discovered ... "suffocate" the bacteria, forcing the bacteria to switch to ...
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... synthesis of recent research findings to inform their management ... states. , The Ecology and Management of Moist ... of the Relevant Biophysical Science and Implications for Future ... U.S. Forest Service,s Pacific Northwest Research Station, is a ... synthesis of the large body of scientific information on ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... of Virginia researchers have discovered that microRNAs, a form of ... , In the May 1 issue of Genes & ... have shown that microRNAs can suppress the overexpression of a ... fatty tissue and certain tumors, as well as diet-induced obesity. ...
... uncovered evidence that baby fish, only millimetres long, manage to ... of open sea by using their sense of smell. , ... Mike Kingsford of the ARC Centre of Excellence for Coral ... Hole, USA, also shines a new light on how the ...
... of York have won a grant of £110,000 to investigate ... Dr Jason Lynam and Dr Ian Fairlamb, of the University's ... Leverhulme Trust for a three-year study into the use of ... the bloodstream. , Carbon monoxide is an anti-inflammatory, and ...
Cached Biology News:Baby fish 'smell their way home' 2Research to spotlight carbon monoxide benefits 2
... a metabolically stable analog of ... uterine stimulant and abortifacient which ... induce labor. It induces luteolysis ... when given as an intramuscular ...
... a member of a class of proteins who ... sequence. Mut S plays an integral role in ... transcription-coupled nucleotide excision repair and in preventing chromosomal ... binds to DNA specifically at base pair mismatches ...
... Glutathione-S-transferases (GSTs) are a group of enzymes ... xenobiotics in mammals. The enzymes protect cells ... of the glutathione to electrophilic xenobiotics, and ... and toxic effects of the compounds. GST ...
... Monoclonal Antibody Epitope: A ... Recommended Storage: Store vial ... contents and freeze at -20 C or below ... and thawing. Centrifuge product if not completely ...
Biology Products: